Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cocrystal Pharma ( (COCP) ) just unveiled an update.
On June 5, 2025, Cocrystal Pharma announced that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium. CDI-988, developed as a norovirus prophylaxis and treatment, represents a potential breakthrough by targeting the virus’ core replication machinery, which could transform how norovirus outbreaks are prevented and treated. The presentation will discuss Phase 1 results, emphasizing the drug’s novel mechanism and its potential impact on military settings where norovirus poses significant operational challenges.
The most recent analyst rating on (COCP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Average Trading Volume: 18,573
Technical Sentiment Signal: Sell
Current Market Cap: $17.09M
For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.